Search
Now showing items 1-6 of 6
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.
(
Taylor & Francis
, 2022 , Article)
This study aims to estimate the prevalence and longevity of detectable SARS-CoV-2 antibodies and T and B memory cells after recovery. In addition, the prevalence of COVID-19 reinfection and the preventive efficacy of ...
Overconfident results with the bivariate random effects model for meta-analysis of diagnostic accuracy studies
(
Wiley
, 2022 , Other)
Meta-analyses of diagnostic accuracy studies are a fundamental component of evidence-based medicine, and they are extensively used in medical imaging and the clinical laboratory. Techniques specifically developed to combine ...
Does the Sex of the Firstborn Child Affect the Breast Cancer Risk and Survival: A Systematic Review and Meta-analysis of Over 1 Million Cases
(
Galenos Yayinevi
, 2022 , Article)
Background: Reports on the risk and prognosis of breast cancer in relation to the sex of a child have been conflicting. Since medical sciences play an important role in informing sociocultural understandings of health and ...
Data reproducibility issues and their potential impact on conclusions from evidence syntheses of randomized controlled trials in sleep medicine
(
Elsevier
, 2022 , Article)
In this study, we examined the data reproducibility issues in systematic reviews in sleep medicine. We searched for systematic reviews of randomized controlled trials published in sleep medicine journals. The metadata in ...
Should studies with no events in both arms be excluded in evidence synthesis?
(
Elsevier
, 2022 , Article)
ObjectivesIn safety assessment, studies with no events are a frequent occurrence when conducting meta-analyses. The current approach in meta-analysis is to exclude double-zero studies from the synthesis. In this study, we ...
Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy
(
Marshfield Clinic
, 2022 , Article)
Objective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in ...